公开(公告)号：US20060276542A1

公开(公告)日：2006-12-07

申请号：US10549998

申请日：2004-03-22

Applicant: Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

Inventor： Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

IPC: A61K31/22 ,  A61K31/195 ,  A61K31/165 ,  A61K31/16

CPC classification number: A61K31/165 ,  A61K31/16 ,  A61K31/195 ,  A61K31/22

Abstract: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract translation: 提供了一种使用α2 N 3亚基钙通道调节剂或其它与α2 Ca钙通道亚基相互作用的化合物与一种或多种具有光滑的化合物 肌肉调节作用，以治疗需要治疗的患者的功能性肠病。 根据本发明，α2 N亚基钙通道调节剂包括GABA类似物，包括加巴喷丁和普瑞巴林，加巴喷丁的稠合双环或三环氨基酸类似物和氨基酸化合物。 具有平滑肌调节作用的化合物包括抗毒蕈碱，β3肾上腺素能激动剂，解痉药，神经激肽受体拮抗剂，缓激肽受体拮抗剂和一氧化氮供体。

公开(公告)号：US20060264509A1

公开(公告)日：2006-11-23

申请号：US10549829

申请日：2004-03-22

Applicant: Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

Inventor： Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

IPC: A61K31/195 ,  A61K31/165

CPC classification number: A61K45/06 ,  A61K31/165 ,  A61K31/195 ,  A61K31/197 ,  A61K31/216 ,  A61K2300/00

Abstract: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract translation: 提供了一种使用α2 N 3亚基钙通道调节剂或与α2-δ钙通道亚基相互作用的其它化合物与一种或多种具有平滑肌的化合物组合的方法 调节作用来治疗疼痛。 根据本发明，α2'亚基钙通道调节剂包括GABA类似物（例如加巴喷丁和普瑞巴林），加巴喷丁的稠合双环或三环氨基酸类似物和氨基酸化合物。 具有平滑肌调节作用的化合物包括抗毒蕈碱，β3肾上腺素能激动剂，解痉药，神经激肽受体拮抗剂，缓激肽受体拮抗剂和一氧化氮供体。

公开(公告)号：US20060217391A1

公开(公告)日：2006-09-28

申请号：US11441905

申请日：2006-05-26

Applicant: Steven Landau

Inventor： Steven Landau

IPC: A61K31/519

CPC classification number: A61K31/505 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to a method of treating at least one symptom of irritable bowel syndrome selected from the group consisting of: abnormal stool frequency, abnormal stool form, abnormal stool passage, passage of mucus and feeling of abdominal distension in a subject in need thereof. In certain embodiments, the pain and discomfort associated with irritable bowel syndrome is also reduced. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.

Abstract translation: 本发明涉及一种治疗肠易激综合征症状的至少一种症状的方法，其特征在于，在有需要的受试者中，粪便异常异常，粪便异常，粪便通过，粘液通过和腹胀感。 在某些实施方案中，与肠易激综合征相关的疼痛和不适也减少。 该方法包括向需要治疗的受试者施用治疗有效量的具有5-HT 3受体拮抗剂活性和NorAdrenaline再摄取抑制剂（NARI）活性的化合物。

公开(公告)号：US20050272719A1

公开(公告)日：2005-12-08

申请号：US11122940

申请日：2005-05-04

Applicant: Steven Landau ,  Cheryl Miller ,  Matthew Fraser

Inventor： Steven Landau ,  Cheryl Miller ,  Matthew Fraser

IPC: A01N43/54 ,  A61K31/00 ,  A61K31/135 ,  A61K31/519 ,  A61K31/535 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K31/00 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Abstract translation: 本发明涉及一种治疗需要治疗的受试者的下尿路疾病的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿。 该方法包括向需要治疗的受试者施用治疗有效量的具有5-HT 3受体拮抗剂活性和NorAdrenaline再摄取抑制剂（NARI）活性的化合物。 本发明还涉及在需要治疗的受试者中治疗下尿路障碍的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿， 包括向所述受试者共同施用第一量的5-HT 3拮抗剂和第二量的NARI，其中第一和第二量一起包含治疗有效量或各自以治疗有效的量存在 量。

公开(公告)号：US20050239890A1

公开(公告)日：2005-10-27

申请号：US11126062

申请日：2005-05-10

Applicant: Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

Inventor： Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

IPC: A61K31/195 ,  A61K31/197 ,  A61K31/216 ,  A61K45/06 ,  A61K31/165

CPC classification number: A61K45/06 ,  A61K31/195 ,  A61K31/197 ,  A61K31/216 ,  A61K2300/00

Abstract: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract translation: 提供了一种使用α2 N 3亚基钙通道调节剂或与α2-δ钙通道亚基相互作用的其它化合物与一种或多种具有平滑肌的化合物组合的方法 治疗和/或减轻与正常和脊髓损伤患者的疼痛和非痛苦的下尿路疾病相关的症状的调节作用。 根据本发明，α2 N亚基钙通道调节剂包括GABA类似物，例如加巴喷丁和普瑞巴林，加巴喷丁的稠合双环或三环氨基酸类似物和氨基酸化合物。 具有平滑肌调节作用的化合物包括抗毒蕈碱，β3肾上腺素能激动剂，解痉药，神经激肽受体拮抗剂，缓激肽受体拮抗剂和一氧化氮供体。

公开(公告)号：US20050026835A1

公开(公告)日：2005-02-03

申请号：US10865225

申请日：2004-06-10

Applicant: Matthew Fraser ,  Steven Landau ,  Edward Burgard

Inventor： Matthew Fraser ,  Steven Landau ,  Edward Burgard

IPC: A61K31/00 ,  A61K31/4015 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/4706 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  C07K5/06 ,  C07K5/065 ,  A61K38/17

CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/4015 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/4706 ,  A61K31/5377 ,  A61K31/55 ,  C07K5/06043 ,  C07K5/06078 ,  A61K2300/00

Abstract: A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.

Abstract translation: 提供了一种使用Cav2.2亚基钙通道调节剂治疗非炎症性胃肠道疾病的方法。

公开(公告)号：US20080105751A1

公开(公告)日：2008-05-08

申请号：US11930903

申请日：2007-10-31

Applicant: Steven Landau

Inventor： Steven Landau

IPC: G06K19/10 ,  G06K19/067

CPC classification number: A63F13/95 ,  A63F13/10 ,  A63F13/213 ,  A63F13/69 ,  A63F13/71 ,  A63F13/822 ,  A63F2300/201 ,  A63F2300/206 ,  A63F2300/609 ,  G06F21/32 ,  G06F21/34 ,  G06Q20/341 ,  G06Q20/4014 ,  G06Q20/409 ,  G06Q50/265 ,  G07F7/0826 ,  G07F7/0846 ,  G07F7/1008 ,  G07F7/122 ,  G07F17/32

Abstract: The present invention provides systems and methods for powered video game playing cards, powered voter authentication cards, powered financial transaction cards, and methods for administering the use of each. The cards generally include a thin, flexible substrate and a battery disposed within the substrate. A dynamic token value generator and/or biometric sensor is disposed within the substrate and is powered by the battery. An electronic display is mounted on the substrate for displaying a token value generated by the dynamic token value generator. The token value is configured to be used in conjunction with a back-end token value secure identification system to provide access to secure electronic information or capabilities.

Abstract translation: 本发明提供了用于动力视频游戏纸牌，动力选民认证卡，动力金融交易卡以及用于管理每种使用的方法的系统和方法。 卡通常包括薄的柔性基板和设置在基板内的电池。 动态令牌值发生器和/或生物测定传感器设置在衬底内并由电池供电。 电子显示器安装在基板上，用于显示由动态令牌值发生器产生的令牌值。 令牌值被配置为与后端令牌值安全识别系统结合使用以提供对安全电子信息或能力的访问。

公开(公告)号：USD539285S1

公开(公告)日：2007-03-27

申请号：US29228720

申请日：2005-04-27

Applicant: Steven Landau

Designer： Steven Landau

公开(公告)号：US20070060652A1

公开(公告)日：2007-03-15

申请号：US11598393

申请日：2006-11-13

Applicant: Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

Inventor： Matthew Fraser ,  Karl Thor ,  Edward Burgard ,  Lee Brettman ,  Steven Landau ,  Daniel Ricca

IPC: A61K31/195 ,  A61K31/165

CPC classification number: A61K45/06 ,  A61K31/195 ,  A61K31/197 ,  A61K31/216 ,  A61K2300/00

Abstract: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Abstract translation: 提供了一种使用α2 N 3亚基钙通道调节剂或与α2-δ钙通道亚基相互作用的其它化合物与一种或多种具有平滑肌的化合物组合的方法 治疗和/或减轻与正常和脊髓损伤患者的疼痛和非痛苦的下尿路疾病相关的症状的调节作用。 根据本发明，α2 N亚基钙通道调节剂包括GABA类似物（例如加巴喷丁和普瑞巴林），加巴喷丁的稠合双环或三环氨基酸类似物和氨基酸化合物。 具有平滑肌调节作用的化合物包括抗毒蕈碱，β3肾上腺素能激动剂，解痉药，神经激肽受体拮抗剂，缓激肽受体拮抗剂和一氧化氮供体。

公开(公告)号：USD536700S1

公开(公告)日：2007-02-13

申请号：US29228724

申请日：2005-04-27

Applicant: Steven Landau

Designer： Steven Landau